Northwest Biotherapeutics Inc NWBO:OTCQB

*Data is delayed | Exchange | USD
Last | 04/24/24 EDT
0.4601quote price arrow down-0.012 (-2.5418%)
Volume
1,170,694
52 week range
0.40 - 1.09
Loading...
  • Open0.49
  • Day High0.5041
  • Day Low0.4601
  • Prev Close0.4721
  • 52 Week High1.09
  • 52 Week High Date09/25/23
  • 52 Week Low0.40
  • 52 Week Low Date08/23/23

Key Stats

  • Market Cap547.505M
  • Shares Out1.19B
  • 10 Day Average Volume1.34M
  • Dividend-
  • Dividend Yield-
  • Beta-0.64
  • YTD % Change-34.37

KEY STATS

  • Open0.49
  • Day High0.5041
  • Day Low0.4601
  • Prev Close0.4721
  • 52 Week High1.09
  • 52 Week High Date09/25/23
  • 52 Week Low0.40
  • 52 Week Low Date08/23/23
  • Market Cap547.505M
  • Shares Out1.19B
  • 10 Day Average Volume1.34M
  • Dividend-
  • Dividend Yield-
  • Beta-0.64
  • YTD % Change-34.37

RATIOS/PROFITABILITY

  • EPS (TTM)-0.06
  • P/E (TTM)-8.08
  • Fwd P/E (NTM)-0.45
  • EBITDA (TTM)-53.983M
  • ROE (TTM)-
  • Revenue (TTM)1.932M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-3,240.11%
  • Debt To Equity (MRQ)-86.69%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Northwest Biotherapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient...
Linda Powers J.D.
Chairperson of the Board, President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer
Address
SUITE 800, 4800 MONTGOMERY LANE
Bethesda, MD
20814
United States